Cell Surgical Network Study for Stromal Vascular Fraction Registered by ClinicalTrials.gov

Rancho Mirage, CA (PRWEB) October 14, 2013 Clinicaltrials.gov, a service of the U.S. National Institutes of Health has registered on their public site an IRB approved safety study from the Cell Surgical Network, Inc.. This study is available for patients with various degenerative and inflammatory conditions to undergo Stromal Vascular Fraction deployment for the evaluation and for the…

Stem cells to treat muscular dystrophies – where are we?

2011 Jan;21(1):4-12. Epub 2010 Nov 4. Stem cells to treat muscular dystrophies – where are we? Meng J, Muntoni F, Morgan JE. The Dubowitz Neuromuscular Centre, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United Kingdom. Abstract The muscular dystrophies are inherited disorders characterised by progressive muscle wasting and weakness. Stem cell…

Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy.

2010;16(8):988-1001 Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy. Wilton SD, Fletcher S Abstract In little more than a decade, induced exon skipping as a therapy to treat Duchenne muscular dystrophy (DMD) has progressed from a concept tested in vitro, to pre-clinical evaluation in mouse and dog models, and recent completion of…

Microdystrophin Delivery in Dystrophin-Deficient (mdx) Mice by Genetically-Corrected Syngeneic MSCs Transplantation.

2010 Sep; 42(7) : 2731-9 Microdystrophin Delivery in Dystrophin-Deficient (mdx) Mice by Genetically-Corrected Syngeneic MSCs Transplantation. Xiong F, Xu Y, Zheng H, Lu X, Feng S, Shang Y, Li Y, Zhang Y, Jin S, Zhang C Abstract Cell transplantation and gene therapy are two promising therapeutical approaches for the treatment on Duchenne Muscular Dystrophy (DMD).…

Stem cell therapies to treat muscular dystrophy: progress to date.

2010 Aug 1;24(4):237-47 Stem cell therapies to treat muscular dystrophy: progress to date. Meregalli M, Farini A, Parolini D, Maciotta S, Torrente Y Abstract Muscular dystrophies are heritable, heterogeneous neuromuscular disorders and include Duchenne and Becker muscular dystrophies (DMD and BMD, respectively). DMD patients exhibit progressive muscle weakness and atrophy followed by exhaustion of muscular…

Flt-1 haploinsufficiency ameliorates muscular dystrophy phenotype by developmentally increased vasculature in mdx mice.

2010 Aug 24; Flt-1 haploinsufficiency ameliorates muscular dystrophy phenotype by developmentally increased vasculature in mdx mice. Verma M, Asakura Y, Hirai H, Watanabe S, Tastad C, Fong GH, Ema M, Call JA, Lowe DA, Asakura A Abstract Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disease caused by mutations in the gene coding for…

Stem cell therapies to treat muscular dystrophy: progress to date.

2010 Aug 1;24(4):237-47 Stem cell therapies to treat muscular dystrophy: progress to date. Meregalli M, Farini A, Parolini D, Maciotta S, Torrente Y Abstract Muscular dystrophies are heritable, heterogeneous neuromuscular disorders and include Duchenne and Becker muscular dystrophies (DMD and BMD, respectively). DMD patients exhibit progressive muscle weakness and atrophy followed by exhaustion of muscular…

Targeting fibrosis in Duchenne muscular dystrophy.

2010 Aug;69(8):771-6 Targeting fibrosis in Duchenne muscular dystrophy. Zhou L, Lu H Abstract Duchenne muscular dystrophy (DMD) is the most common genetic muscle disease affecting 1 in 3,500 live male births. It is an X-linked recessive disease caused by a defective dystrophin gene. The disease is characterized by progressive limb weakness, respiratory and cardiac failure,…

Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans

2010 Jul;160(6):1550-60 Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. Sciorati C, Buono R, Azzoni E, Casati S, Ciuffreda P, D’Angelo G, Cattaneo D, Brunelli S, Clementi E Abstract Current therapies for muscular dystrophy are based on corticosteroids. Significant side effects associated with these…